… on challenges associated with the changing epidemiology, development of secondary
infections and treatment of … and treatment of MRSA, which we believe deserve special attention. …

… Staphylococcus aureus is a major cause of nosocomial and community-acquired infections
and … review is to discuss treatment challenges for biofilm-related infections caused by S. …

… This ever-changing phenotype of resistance and virulence is leading to new challenges
and changes in the prevention and treatment of infection in the surgical patient. …

… aureus (MSSA) not treated with this antibiotic in some studies, suggesting that reduced
vancomycin susceptibility could itself be a marker for some other intrinsic property of these …

… glycopeptides that pose a problem in treating infections caused by these pathogens.
Vancomycin is the treatment of choice in treating methicillin-resistant S. aureus (MRSA). Community…

… In fact, vancomycin may no longer be the “automatic antibiotic of choice” for treatment of …
been correlated with treatment failures. Of particular concern, many treatment failures have now …

… and challenges of nanoparticles in enhancing the S. … aureus mastitis treatment are highlighted.
This review will provide the readers with enough information about the challenges of the …

… Mortality, morbidity, and cost from invasive Staphylococcus aureus infections remain
disturbingly high despite the introduction of several new antibiotics to treat methicillin-resistant S. …

… Staphylococcus aureus is the most … Staphylococcus aureus (MRSA) nasal screening in
this disease has not been elucidated. We sought to identify risk factors and outcomes for S. …

… Staphylococcus aureus is the leading cause of hospital-acquired infections and can cause
… a challenge to manage due to its ability to rapidly develop resistance to antibiotic treatment …